CA9 and neoplasm: Combination immunotherapy that consists of human anti-carbonic anhydrase IX (CAIX)-targeted CAR-T cells engineered to secrete human PD-L1 antibodies at the tumor site showed effective regression of renal cell carcinoma in a humanized mouse model [54].